Assembly Biosciences, Inc. (ASMB) Stock Price & Analysis

Assembly Biosciences, Inc. (ASMB) is trading at USD 22.36, down 0.62% today, as of November 18, 2026 at 20:43 UTC (US market open; quotes may be delayed), according to Nexqual market data.

ASMB last closed at USD 22.36; today's session has ranged USD 22.07–23.5 on volume of 342,644 shares. Market capitalization is —, with a 52-week range of USD 19.2–39.71 (NMS). Source: Nexqual, retrieved November 18, 2026 at 20:43 UTC.

What changed for ASMB since Aug 31, 2025

The built-in knowledge of several widely used AI models ends around Aug 31, 2025. Everything below is newer, dated and sourced (as of Nov 18, 2026).

Also available as compact Markdown for AI agents: nexqual.com/ASMB.md

Key facts (ASMB)

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ASMB)

USDFY2021FY2022FY2023FY2024FY2025TTM
Revenue$6.3M$0K$7.2M$28.5M$72.3M$67.0M
Operating income-$133M-$94.1M-$64.6M-$45.4M-$12.1M-$21.3M
Net income-$130M-$93.1M-$61.2M-$40.2M-$6.1M-$11.1M
EPS (diluted)-$36.00-$23.08-$13.38-$6.69-$0.55—
Free cash flow-$96.5M-$84.6M$22.5M-$51.1M-$41.2M-$40.7M
Operating margin-2121.7%—-902.5%-159.3%-16.8%-31.8%
Net margin-2076.4%—-854.8%-140.9%-8.5%-16.6%
Revenue growth-92.1%-100.0%—+298.2%+153.5%—
Cash + short-term investments$147M$91.6M$130M$112M$248M—

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Sep 30, 2026) (ASMB)

Insider sales (SEC Form 4, open-market, last ~7 months) (ASMB)

0 of 5 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

Trade dateInsiderRoleSharesValue% of holdings sold10b5-1 planInsider type
2026-11-02Bjorkquist Jeanette MPFO and PAO727$14K4%NoOpportunistic (traded every year 2023–2025, no repeating month)
2026-11-02White Nicole SChief Manufacturing Officer2,593$51K4.2%NoOpportunistic (traded every year 2023–2025, no repeating month)
2026-11-02Gaggar AnujChief Medical Officer2,593$51K4.6%NoToo little history (no open-market trades in 2023–2025)
2026-11-02Okazaki Jason ACEO and President6,202$122K3.1%NoRoutine (sold in Mar each year 2023–2025; this trade is outside those months)
2026-06-17Bjorkquist Jeanette MPFO and PAO29$1K0.2%NoOpportunistic (traded every year 2023–2025, no repeating month)

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (ASMB)

Rating changes, last 120 days:

DateFirmActionRatingPrice target
2026-11-03UBSTarget loweredBuy$52 → $48
2026-09-01MizuhoTarget loweredOutperform$53 → $45
2026-09-01UBSInitiatedBuy$52
2026-08-18HC Wainwright & Co.ReiteratedBuy$50

Total return (dividends reinvested) (ASMB)

1Y (from 2025-11-18)5Y (from 2021-11-15)
Total return-37.7%-19.0%
S&P 500 (SPY)+11.9%+66.7%
Per year-37.7%-4.1%
Volatility (annualized)60.1%58.9%
Max drawdown-49.3% (Nov 2025→Nov 2026)-69.8% (Nov 2021→Oct 2023)

Dividends (ASMB)

ASMB paid no cash dividend in the last five years.

Short interest (ASMB)

3,032,675 shares sold short, 19.82% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 2,822,392 shares (+7.5%). Days to cover: 13.6 (short shares ÷ average daily volume).

ASMB earnings history and stock reaction

Results filedQuarterEPSConsensusSurpriseStock reaction
—Quarter ended Sep 30, 2026−$0.93−$0.49Miss −89.8%—
—Quarter ended Jun 30, 2026−$0.20−$0.67Beat +70.1%—
—Quarter ended Mar 31, 2026−$0.54−$0.64Beat +15.6%—
—Quarter ended Dec 31, 2025$2.48−$0.85Beat +$3.33—

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

ASMB recent SEC filings (last 120 days)

FiledFormWhat it says
Nov 16, 2026Schedule 13G/AJANUS HENDERSON GROUP Ltd.: 3.3% of shares, passive 5%+ holder (amended)
Nov 12, 202610-QQuarterly report · period ended Sep 30, 2026
Nov 12, 20268-KQuarterly results
Aug 14, 2026Schedule 13G/AParadigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC: 7.8% of shares, passive 5%+ holder (amended)
Aug 14, 20268-K/AQuarterly results
Aug 13, 202610-QQuarterly report · period ended Jun 30, 2026
Aug 13, 20268-KCompleted an acquisition or sale of assets
Aug 13, 2026Schedule 13G/AJANUS HENDERSON GROUP Ltd.: 6.9% of shares, passive 5%+ holder (amended)
Aug 4, 2026Schedule 13G/AFarallon Capital Management, L.L.C., Farallon Capital Partners, L.P.: 8.1% of shares, passive 5%+ holder (amended)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

ASMB suppliers, customers and competitors (named in its 10-K)

RelationshipCompanySentence in the filing
PartnerGILEAD SCIENCES, INC. (GILD)“our ability to realize the potential benefits of our collaboration with Gilead Sciences, Inc. (Gilead), including all financial aspects of the collaboration and equity investments;”
PartnerArbutus Biopharma Corp (ABUS)“Reflects net amounts refundable to us after final reconciliation of costs for the clinical trial conducted pursuant to the Clinical Trial Collaboration Agreement with Arbutus Biopharma Corporation, which was terminated in February 2023.”

Quoted from the company's 10-K filed Mar 19, 2026.

ASMB company outlook (results filed Nov 12, 2026)

Quoted word-for-word from the SEC 8-K results press release.

ASMB analyst estimates and revisions

PeriodEPS estimate90 days agoChangeRevenue estimateAnalysts
Current quarter (ends Dec 2026)$1.29$1.37-5.8%$42.8M3
Next quarter (ends Mar 2027)$-0.25$0.02−$0.27$10.6M1
Current fiscal year (ends Dec 2026)$-0.55$0.42−$0.97$56.6M2
Next fiscal year (ends Dec 2027)$-2.72$-1.89−$0.83$33.3M4

Key Statistics (as of November 18, 2026 at 20:43 UTC)

PriceUSD 22.36
Change▼ 0.62% (down)
Previous CloseUSD 22.36
OpenUSD 22.36
Day RangeUSD 22.07 – 23.5
52-Week RangeUSD 19.2 – 39.71
Volume342,644 shares
Market Cap—
ExchangeNMS

Technical Analysis (ASMB)

Nexqual's technical model rates ASMB "NEUTRAL" based on 2 bullish and 3 bearish signals across 129 daily candles, as of November 18, 2026 at 20:43 UTC.

Overall SignalNEUTRAL
RSI (14)55.88 (neutral)
vs SMA50Below (USD 22.48)
MACD-0.16 (negative)

Earnings (ASMB)

EPS EstimateUSD 1.29
Revenue Estimate$42.84M

Recent Earnings History

QuarterActual vs Estimate
2026-09-30USD -0.93 vs est -0.49 ▼ miss
2026-06-30USD -0.2 vs est -0.67 ▲ beat
2026-03-31USD -0.54 vs est -0.64 ▲ beat
2025-12-31USD 2.48 vs est -0.85 ▲ beat

Source: Nexqual, November 18, 2026 at 20:43 UTC.

Financials & Fundamentals (ASMB)

Total Revenue$67.01M
Revenue Growth (latest quarter, YoY)-72.60%
Gross Margin-0.43%
Operating Margin-31.83%
Profit Margin-16.57%
ROE-4.61%
Debt / Equity0.01
Current Ratio12.89
Total Cash$314.26M
Total Debt$2.21M
Free Cash Flow (last four quarters to Sep 2026, SEC 10-Q / 10-K)-$40.68M (-60.7% of revenue)

Source: Nexqual, November 18, 2026 at 20:43 UTC.

Financial Health Score (ASMB)

Nexqual rates Assembly Biosciences, Inc.'s overall financial health "Mixed" across five dimensions, as of November 18, 2026 at 20:43 UTC.

GrowthStrong — Revenue +80% (last 4 quarters to Sep 2026 vs the 4 before, SEC)
ProfitabilityCritical — Gross margin -0%, operating -32% (last 12 months)
Balance SheetStrong — $314M cash vs $2M debt, net cash position
Cash FlowWeak — FCF negative: -$41M (last 4 quarters to Sep 2026, SEC), burning cash
EfficiencyCritical — ROE -4%, ROA -3.4% (last 4 quarters, SEC)

Ownership (ASMB)

Insider Ownership+27.83%
Institutional Ownership+70.78%
Shares Outstanding20.48M
Float10.28M
Short % of Float+19.82%

Source: Nexqual, November 18, 2026 at 20:43 UTC.

From Assembly Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)

Partnerships

Legal & Regulatory Risks (Item 1A, quoted)

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

SymbolNamePriceChange
KODKodiak Sciences IncUSD 98.14▲ 1.38%
BLTEBelite Bio, IncUSD 157.14▼ 0.37%
ORKAOruka Therapeutics, Inc.USD 95.92▼ 0.42%
IMVTImmunovant, Inc.USD 33.3▲ 0.27%
AXSMAxsome Therapeutics, Inc.USD 133.9▼ 1.51%
IBRXImmunityBio, Inc.USD 6.71▲ 7.19%

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 20:43 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt